openPR Logo
Press release

Cyclin-Dependent Kinase Inhibitors Therapeutics Key Players Analysis - Merck, Eli Lilly and Company, AstraZeneca, Boehringer Ingelheim

Cyclin-Dependent Kinase Inhibitors Therapeutics Key Players

The study analyzed that the CDK inhibitors therapeutics pipeline comprises approximately 24 drug candidates in different stages of development.

CDKs are the catalytic subunits of serine or threonine protein kinases that regulate the checkpoints in the cell cycle to control the proliferative capacity of cancerous cells. These proteins form cyclin-CDK complex which gets activated after phosphorylation, leading to cell proliferation.

Download report sample at: http://bit.ly/2eqiPu5

**Various collaborations for CDK inhibitors drug development

Eli Lilly and Company and Boehringer Ingelheim GmbH entered into a collaboration for clinical studies of their drug candidates in combination, in patients diagnosed with HR+, HER2-metastatic breast cancer.

Some of the key players developing drugs as CDK inhibitors for the treatment of various indications include Eli Lilly and Company, Merck & Co., AstraZeneca plc and others.

Browse report at: http://bit.ly/2QU5dZs

**Various drug designations for CDK inhibitors drug development

USFDA granted Breakthrough Therapy Designation to a drug candidate of Eli Lilly and Company which is being developed for the treatment of refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer. This will facilitate the development and expedite the review of drug candidate for the treatment of refractory HR+ advanced or metastatic breast cancer.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
347 5th Ave. #1402- 210
New York City, NY 10016 United States
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Cyclin-Dependent Kinase Inhibitors Therapeutics Key Players Analysis - Merck, Eli Lilly and Company, AstraZeneca, Boehringer Ingelheim here

News-ID: 1386850 • Views:

More Releases from P&S Intelligence - Pharmaceuticals

Systemic Lupus Erythematosus Pipeline Analysis - Anthera Pharmaceuticals, Inc., Genentech, Inc., Merck KGaA
Systemic Lupus Erythematosus Pipeline Analysis - Anthera Pharmaceuticals, Inc., …
The study analyzed that the systemic lupus erythematosus pipeline comprises of 57 drug candidates in different stages of development. Explore report sample at: https://www.psmarketresearch.com/market-analysis/systemic-lupus-erythematosus-pipeline-analysis/report-sample Systemic lupus erythematosus is a type of lupus in which the immune system damages its own tissues. The disease affects many parts of the body including skin, joints, lungs, brain, blood vessels and kidneys. The systemic lupus erythematosus is caused by impaired immune system due to which the
Herpes Simplex Virus Infections Therapeutic - Pipeline Analysis, Clinical Trials and Developments
Herpes Simplex Virus Infections Therapeutic - Pipeline Analysis, Clinical Trials …
The study analysed that the Herpes simplex virus infections pipeline comprises of 20 drug candidates in different stages of development. As per the findings of the research, most of the drug candidates are being developed to be administered by oral route. Explore report sample at: https://www.psmarketresearch.com/market-analysis/hsv-infections-therapeutics-pipeline-analysis/report-sample Many technologies are being developed that offer promising innovative treatments which can control the progression of Herpes simplex virus infections. The technologies include, but not limited to,
Japanese Encephalitis Therapeutics - Pipeline Analysis, Clinical Trials, Patent and Collaborations
Japanese Encephalitis Therapeutics - Pipeline Analysis, Clinical Trials, Patent …
Japanese encephalitis is a viral infection that spreads by mosquito bites. The study analyzed that the Japanese encephalitis therapeutics pipeline comprises approximately 12 drug candidates in different stages of development. Explore report sample at: https://www.psmarketresearch.com/market-analysis/japanese-encephalitis-therapeutics-pipeline/report-sample The companies developing drugs for the treatment of Japanese encephalitis are laying more emphasis on the drug candidates to be developed as vaccines, due to the promising results shown by these candidates the in the clinical development.
mTOR Inhibitors Therapeutics Pipeline - Analysis, Clinical Trials, Collaborations and Developments
mTOR Inhibitors Therapeutics Pipeline - Analysis, Clinical Trials, Collaboration …
According to the research findings, most of the drug candidates that act as mTOR inhibitors are being developed as small molecules, further supported by the fact that small molecules have several advantages such as it can be manufactured with production rate higher than any other molecule types. Explore report sample at: https://www.psmarketresearch.com/market-analysis/mtor-inhibitors-therapeutics/report-sample The positive clinical results of mTOR inhibitors drug candidates is a key factor driving the pipeline growth. For instance, F.

All 5 Releases


More Releases for CDK

Investigation ongoing for Investors in CDK Global, Inc. (NASDAQ: CDK) over poten …
An investigation on behalf of investors in shares of CDK Global, Inc. (NASDAQ: CDK) was announced over potential breaches of fiduciary duties by certain officers and directors at CDK Global, Inc. Investors who purchased shares of CDK Global, Inc. (NASDAQ: CDK) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain CDK Global, Inc. directors breached
Cancer CDK Inhibitors Market 2021 | Detailed Report
According to Market Study Report, Cancer CDK Inhibitors Market provides a comprehensive analysis of the Cancer CDK Inhibitors Market segments, including their dynamics, size, growth, regulatory requirements, competitive landscape, and emerging opportunities of global industry. An exclusive data offered in this report is collected by research and industry experts team. Get Free Sample PDF (including full TOC, Tables and Figures) of Cancer CDK Inhibitors Market @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5087783 The report provides a
CDK Websites See Significant Organic Traffic Increases
REUNION MARKETING Data Beats Intuition 418 S. Dawson St. Raleigh, North Carolina 27601 NEWS RELEASE For Immediate Release CDK Websites See Significant Organic Traffic Increases The Recent Google Algorithm Affected Traffic Flows Across CMSs August 20, 2018 — Reunion Marketing personnel noted a remarkable increase in organic traffic for CDK websites that directly coincides with a Google algorithm update. While conducting regular audits, members of the Reunion team discovered a pattern of significant increases in organic website traffic throughout
Dealer Management Market Excellent Growth | IBM, CA, Cox Automotive, CDK Global
The qualitative research study conducted by HTF MI titled “Global Dealer Management Market Size, Status and Forecast 2025” provides primary Data, surveys, Scope of the Product and vendor briefings. The market dynamic forces have been determined after conducting a detailed study of the Global Dealer Managementmarket. The study provides forecasts for Dealer Management investments till 2022. If you are involved in the Dealer Management industry or intend to be, then
Global Cancer CDK Inhibitors Market and Clinical Pipeline Outlook 2022 Report
“Global Cancer CDK Inhibitors Market and Clinical Pipeline Outlook 2022” report highlights: * Selectivity and Working Mechanism of a Cancer CDKs Inhibitor * Recent Advances in the CDKs Related Cancer Therapy * Global Cancer CDK Inhibitors Clinical Trials Insight: 45 Drugs in Pipeline * Market Opportunity Assessment: More Than US$ 20 Billion (2022) * Price Analysis of Cancer CDKs Inhibitors: * Sales Analysis of Available Drugs: More Than US$ 2 Billion (2017) Download Report Sample Weblink:
Download Global Cancer CDK Inhibitors Market and Clinical Pipeline Outlook 2022
“Global Cancer CDK Inhibitors Market and Clinical Pipeline Outlook 2022” report gives comprehensive insight on clinical and non-clinical parameters related to emergence and growth of CDK inhibitors in cancer therapy. As per report findings, CDK inhibitors have emerged as new growth frontier for the organizations involved in the research, development, licensing and commercialization of targeted cancer therapies. There are 2 CDK inhibitors commercially available in the market for the treatment